Corrigendum to "Identifying chronic alcoholism drug disulfiram as a potent DJ-1 inhibitor for cancer therapeutics" [Eur. J. Pharmacol. 926 (2022) 175035]
Eur J Pharmacol. 2023 Mar 5:942:175527.
doi: 10.1016/j.ejphar.2023.175527.
Epub 2023 Jan 25.
1 Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
2 The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China.
3 Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China; Cancer Center of Zhejiang University, Hangzhou, China.
4 Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China.
5 Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China. Electronic address: jiangli49@zju.edu.cn.
6 The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China. Electronic address: ymeng6030@zjuaim.com.
7 Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China; The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, China; Cancer Center of Zhejiang University, Hangzhou, China. Electronic address: caoji88@zju.edu.cn.